<DOC>
	<DOCNO>NCT02304484</DOCNO>
	<brief_summary>To characterize safety tolerability long-term administration evolocumab subject know coronary artery disease hypercholesterolemia</brief_summary>
	<brief_title>Extension ( OLE ) Study Assess Safety Efficacy Evolocumab</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Completed week 80 study 20120153 . Did complete IP 20120153 parent study Have unstable medical condition , judgment investigator Known sensitivity product administer dose Currently enrol another investigational device drug study ( exclude evolocumab ( AMG 145 ) parent study ) , less 30 day since end another investigational device drug study ( ) , receive investigational agent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>